

Evaluation of Serum Levels of Adiponectin in Egyptian Patients with Hepatitis C Related Chronic Liver Disease

THESIS

*Submitted for partial fulfillment of
Master degree (M.Sc) in
Tropical Medicine*

By

Samah Abd El -Hafez Megahed
(M.B.; B.Ch. Cairo University)

Under the supervision of

Dr. Iman Ismail Ramzy

*Professor of Tropical Medicine
Faculty of Medicine
Cairo University*

Dr. Hasan Ahmed Elgarem

*Professor of Tropical Medicine
Faculty of Medicine
Cairo University*

Dr. Hisham Ibrahim Elmakhzangy

*Lecturer of Tropical Medicine
Faculty of Medicine
Cairo University*

Faculty of Medicine
Cairo University
2007

Acknowledgement

"First and foremost thanks to god. Who always blessed my work and who sent me those who were of help".

Words will never be able to express my deepest gratitude to all those who helped me to make this piece of work possible.

*I am honored to start with plentiful of thanks, appreciation and deepest feeling of gratitude and respect to the virtuous **Dr. Iman Ismael Ramzy**, professor of Tropical Medicine, Cairo University, for her civility of supervision and for her mason and fruitful instructions. She patiently gave me much of her time, experience, knowledge, directions and support.*

*Also I have to precede with thanking **Dr. Hassan Ahmad el-Garem**, Assistant professor of Tropical Medicine, Cairo University, for his supervision despite his limited time. I extend my sincere gratitude to **Dr. Hisham Ibrahim el-Makhsangy**, lecturer of Tropical Medicine, for his support and his continuous encouragement through the course of this work.*

*I would like to express my sincere appreciation and praise to the kind help of **Dr. Wafaa Elaakel**, Assistant professor of Tropical Medicine. I would like also to thank **Dr. Sahar Abdulaaty**, Assistant professor of Clinical and Chemical Pathology, for her help to try achieving perfection in this work with providing the accurate results.*

Special thanks to Bilharzial Liver Unit and Dr. Gamal Esmat professor of Tropical Medicine, Cairo University and the director of the unit who provided us with much financial and scientific support.

I would also like to thank my colleagues and staff members at the National Research Institute of Tropical Medicine and Liver Disease for their continuous effort and help to make me produce this work,

And please, let me direct my truthful and gratitude feelings and due thanks to all my family, my parents, my brothers and sisters and I am especially grateful to my husband. I will be happy to precede my thanks for every one who honored me and attended this day.

Finally, I pray to god to accept my modest work, If I did well, it will because of God's help; and if I didn't, it is enough that I strived and did my best.

ABSTRACT

Introduction:

Adipose tissue secretes a number of biologically active adipokines one of them is Adiponectin. However there is no data about the secretion of adiponectin during hepatitis C infection, some studies revealed that in chronic HCV patient's hypoadiponectinemia is significantly associated with the development of liver steatosis. Adiponectin may be an attractive therapy for fatty liver disease.

Aim of the work:

The aim of this study is to define a potential role of adiponectin in patients with chronic hepatitis C virus infection in Egypt and to investigate its role in HCV-related steatosis.

Subjects and Methods:

The present study was conducted on forty-four patients suffering from chronic hepatitis C and sixteen healthy volunteers served as controls. The subjects selected from the National Research Institute for Tropical Medicine and Liver Disease.

Results:

The significant finding of this study is that the chronic HCV patients have reduced circulating adiponectin levels than healthy controls (12.7 ± 8.2 for HCV vs. 19.5 ± 11.6 for control, $P = 0.04$). The results of the present study suggest that there is no significant correlation seen between adiponectin and steatosis as well as the grades of steatosis as mean adiponectin level is 9.00 ± 7.45 in steatosis $< 30\%$ while it is 14.50 ± 2.12 in steatosis $> 30\%$ ($P = 0.29$).

Conclusion:

In conclusion, this study demonstrates that hypoadiponectinaemia in HCV-infected patients did not correlate with hepatic steatosis.

Key words: Adiponectin, HCV, Steatosis

CONTENTS

Acknowledgment	
Introduction -----	<i>1</i>
Aim of the work-----	<i>5</i>
Review of literature:	
Adiponectin:	
<i>Definition-----</i>	<i>6</i>
<i>Structure -----</i>	<i>6</i>
<i>Forms and isoforms-----</i>	<i>8</i>
<i>Receptors and their regulation-----</i>	<i>9</i>
<i>Mechanisms of action -----</i>	<i>12</i>
<i>Adiponectin secretion-----</i>	<i>18</i>
<i>Adiponectin regulation and excretion-----</i>	<i>19</i>
<i>Adiponectin as therapeutic agent-----</i>	<i>20</i>
HCV and chronic hepatitis:	
<i>Definition-----</i>	<i>22</i>
<i>Etiology -----</i>	<i>22</i>
<i>HCV : Virology-----</i>	<i>23</i>
<i>Epidemiology -----</i>	<i>25</i>
<i>Mode of transmission -----</i>	<i>27</i>
<i>Mechanisms of infection -----</i>	<i>28</i>
<i>Cell entry and translation-----</i>	<i>28</i>
<i>Clinical presentation-----</i>	<i>29</i>
<i>Complications-----</i>	<i>31</i>
<i>Diagnosis -----</i>	<i>32</i>
<i>Treatment -----</i>	<i>34</i>
<i>Hepatic steatosis-----</i>	<i>37</i>

<i>HCV in Egypt -----</i>	<i>39</i>
Relation of adiponectin to HCV infection:	
<i>Introduction-----</i>	<i>41</i>
<i>Previous studies-----</i>	<i>43</i>
Subjects and methods-----	<i>49</i>
Results -----	<i>55</i>
Discussion -----	<i>72</i>
Summary and conclusion-----	<i>79</i>
Recommendations -----	<i>83</i>
References -----	<i>84</i>
Arabic summary	

LIST OF ABBREVIATIONS

- ACC : Acetyl co-enzyme A
- Acrp 30 : Adipocyte complement- related protein 30.
- Adipo R1 : Adiponectin receptor 1.
- Adipo R2 : Adiponectin receptor 2.
- ALT : Alanine transferase.
- AMPK : Adenosine monophosphate kinase.
- APM1 : Adipose most abundant gene transcript 1.
- AST : Aspartate transferase.
- BMI : Body mass index.
- CAMP : Cyclic adenosine monophosphate.
- EIA : Enzyme immunoassay
- ELISA : Enzyme linked immunosorbant assay.
- FFA : Free fatty acids.
- GPCRs : G protein- coupled receptors.
- HCV : Hepatitis C virus.
- HCC : Hepatocellular carcinoma.
- HSc : Hepatic stellate cells.
- HSF : Highly saturated fats.
- HMW : High molecular weight.
- IGF-1 : Insulin like growth factor 1
- IL-10 : Interluekin 10
- IRES : Internal ribosomal entry site.
- KDa : Kilodalton: unified atomic mass unit.
- LDLR : Low density lipoprotein receptor.
- LMW : Low molecular weight.
- NAFLD : Non alcoholic fatty liver disease.
- NTR : None translated region.

- ORF : Open reading frame.
- PI : Phosphatidyle inositol.
- PPAR α : Peroxisome proliferators activated receptor alpha ligand
- Pref-1/dlk1: Preadipocyte factor 1 / delta-like 1
- RIBA : Recombinant immunoblot assay.
- RT-PCR : Reverse transcriptase – polymerase chain reaction.
- SR-B1 : Scavenger receptor class B type 1.
- SREBP-1C: Sterol regulatory element-binding protein 1C
- T 1/2 : Half life.
- TG : Triglycerides.
- TNF- α : Tumour necrosis factor alpha
- 7 TM : Seven -transmembrane receptor.
- WAT : White adipose tissue.

LISTS OF FIGURES

1) Figures of Review

	<i>TITLE</i>	<i>PAGE</i>
<i>A</i>	Adiponectin domains	<i>7</i>
<i>B</i>	Structure of a G protein coupled receptors	<i>8</i>
<i>C</i>	Adiponectin receptors	<i>10</i>
<i>D</i>	Molecular mechanisms of adiponectin action	<i>10</i>
<i>E</i>	Obesity and adiponectin resistance	<i>11</i>
<i>F</i>	Adiponectin actions in the liver and skeletal muscles	<i>13</i>
<i>G</i>	Antiatherosclerotic effect of adiponectin	<i>14</i>
<i>H</i>	Effect of decreased adiponectin on the process of atherosclerosis	<i>15</i>
<i>I</i>	Summary of putative functions of adiponectin in protecting hepatocytes	<i>16</i>
<i>J</i>	A hypothetical model for the secretion and action of adiponectin	<i>20</i>
<i>K</i>	Hepatitis C virus: model structure and genome organization	<i>24</i>
<i>L</i>	Life cycle of the virus C in a host cell	<i>29</i>
<i>M</i>	Translation and polyprotein processing of virus C	<i>29</i>
<i>N</i>	The natural history of HCV infection	<i>30</i>

2) Figures of results

	<i>TITLE</i>	<i>PAGE</i>
<i>i</i>	Mean levels of liver enzymes in both groups	<i>56</i>
<i>ii</i>	Mean levels of lipid profile in both groups	<i>56</i>
<i>iii</i>	Mean adiponectin levels among the studied groups	<i>57</i>
<i>iv</i>	Valid percent of ultrasound findings in the HCV group	<i>58</i>
<i>v</i>	Valid percent of HAI grades in HCV patients	<i>59</i>
<i>vi</i>	Valid percent of fibrosis grades in the biopsied patients	<i>70</i>
<i>vii</i>	Valid percent of PCR levels in the HCV group	<i>62</i>
<i>viii</i>	Mean adiponectin levels among males and females in the HCV group	<i>64</i>
<i>ix</i>	Mean adiponectin levels among males and females in the control group	<i>65</i>
<i>x</i>	Correlation between adiponectin and BMI in chronic HCV patients	<i>66</i>
<i>xi</i>	Correlation between adiponectin and ultrasonographic findings of the HCV group	<i>67</i>
<i>xii</i>	Correlation between adiponectin and steatosis in the HCV group	<i>69</i>

LIST OF TABLES

	<i>TITLE</i>	<i>PAGE</i>
1	HCV variants all over the world	26
2	Modified knodell score (HAI)	53
3	The main clinical and laboratory data of the studied group	55
4	Mean adiponectin levels of the studied groups	57
5	Ultrasound description in the HCV studied group	58
6	Description of the HAI grades in the HCV patients	58
7	Description of the activity score among the 37 biopsied patients	59
8	Description of the grades of fibrosis among the 37 biopsied patients	60
9	Steatosis in the sampled patients of the HCV group	61
10	PCR levels in the HCV patients group	61
11	Correlation between adiponectin and various parameters among the HCV group	63
12	Mean adiponectin levels among males and females in the HCV group	64
13	Mean adiponectin levels among males and females in the control group	64
14	Correlation between adiponectin and BMI in the HCV patients with BMI <25	65
15	Correlation between adiponectin and BMI in HCV patients with BMI 25-30	66
16	Correlation between adiponectin and BMI in control group with BMI <25	66

17	Correlation between adiponectin and BMI in control group with BMI 25-30	77
18	Correlation between adiponectin and ultrasonographic findings of the HCV group	68
19	Correlation between adiponectin and liver biopsies results(activity & fibrosis)	68
20	Correlation between adiponectin and HCV groups with and without steatosis	69
21	Correlation between adiponectin and steatosis groups	70
22	Comparison of adiponectin in relation to the level of viraemia	70
23	Comparison of lipid profile in relation to the level of viraemia	71

INTRODUCTION

INTRODUCTION

Approximately 200 millions people are chronically infected with hepatitis C virus (HCV) in the world (**Liagpunsakul& Chalasani, 2004**). HCV accounts for 20% of cases of acute hepatitis, 70% of cases of chronic hepatitis, 40% of cases of end stage cirrhosis, 60% of cases of hepatocellular carcinoma (HCC) and 30% of liver transplantation. It is the most frequent indication for hepatic transplantation (**Consensus, 1999**).

About 85% of those infected with HCV will not clear the virus and will develop chronic hepatitis of varying severity (**Marcellin, 1999**). In approximately 1/3 of patients, ALT is normal despite detectable HCV RNA in serum. Hepatic histology shows only mild disease, hepatic fibrosis progression and activity are also lower (**Jamal, 1999; Marcellin, 1999**) in the remaining 2/3 ALT is elevated usually 2 – 10 times. Mild chronic hepatitis affects 50%, moderate or severe chronic hepatitis is seen in about 50% of newly diagnosed patients. Liver biopsy remains the most accurate way of distinguishing mild from moderate or severe chronic hepatitis (**Barkhuizen et al., 1999**).

Chronic hepatitis C is characterized by several histological features ranging from bile duct damage, lymphoid follicles, steatosis and fibrosis. Although up to 30% of patients with chronic hepatitis C may develop cirrhosis, little is known about factors that determine increasing fibrosis and progressive disease in an individual (**Piche et al., 2004**).

Adipose tissue has traditionally been considered as an energy storage organ but over the last decade, a new role has emerged as an important endocrine organ (**Ahima et al., 2000**).

Adipose tissue secretes a number of biologically active adipokines which is a variety of hormones including Leptin, Resistin, Ghrelin and Adiponectin. The protein leptin, a satiety hormone, regulates appetite and energy balance of the body. Increased Resistin concentration might cause insulin resistance and thus could link obesity with type 2 diabetes. Ghrelin is produced in the stomach and involved in short term regulation of feeding and long term regulation of energy metabolism and lastly adiponectin could suppress the development of atherosclerosis and liver fibrosis and might play a role as an anti inflammatory hormone. These hormones directly influence other organ systems including the brain, liver and skeletal muscle and are significantly regulated by the nutritional status (**Ursula& Axel, 2004**).

Leptin is a highly hydrophobic 16 KDa protein hormone composed of 167 amino acid residue polypeptide. It is encoded by a gene called the obese gene. It is expressed predominantly in adipocytes. Smaller amounts also secreted by stomach and placenta (**Zhang, 1997**).

Leptin exhibiting many important effects; as an adipostat and body weight regulator, glucose homeostasis through antagonizing insulin signaling in hepatocytes leading to increased glycogenolysis and gluconeogenesis and it has angiogenic activity as it induces neovascularization. Leptin plays a crucial role in liver fibrosis. Activated, but not quiescent, hepatic stellate cells express